Sinovac up 6% premarket

|About: Sinovac Biotech, Ltd. (SVA)|By:, SA News Editor

Shares of Sinovac Biotech (SVA) are poised for a modest pop this morning in response to its earnings release.

Cash and equivalents totaled $107.2M at year end.

Consensus estimates for 2014 and 2015 are a loss of $0.05/share on revenues of $81M and earnings of $0.15/share on revenues of $108M, respectively.

25 mutual funds have positions, up from 24 a year earlier.